In vivo tau imaging in Alzheimer's disease and other dementias

Comparison of F-18-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL (R) approaches: Validation against histopathology

Vincent Dore, Santiago Bullich, Christopher C Rowe, Pierrick Bourgeat, Salamata Konate, Osama Sabri, Andrew W Stephens, Henryk Barthel, Jurgen Fripp, Colin L Masters, Ludger Dinkelborg, Olivier Salvado, Victor L Villemagne, Susan De Santi

2019-06-01

INTRODUCTION: 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recru..

Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions

Victor L Villemagne, Vincent Dore, Samantha C Burnham, Colin L Masters, Christopher C Rowe

2018-04-01

Most neurodegenerative disorders are associated with aggregated protein deposits. In the case of Alzheimer disease (AD), extracell..

F-18-Florbetaben PET beta-amyloid binding expressed in Centiloids

Christopher C Rowe, Vincent Dore, Gareth Jones, David Baxendale, Rachel S Mulligan, Santiago Bullich, Andrew W Stephens, Susan De Santi, Colin L Masters, Ludger Dinkelborg, Victor L Villemagne

2017-11-01

PURPOSE: The Centiloid (CL) method enables quantitative values from Aβ-amyloid (Aβ) imaging to be expressed in a universal unit pr..

Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle

CJ Perry, AJ Lawrence

2017-01-01

Any type of behavioral change is an effortful process. Thus, the process of behavioral therapy, where clients seek to change malad..

Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions

Victor L Villemagne, Nobuyuki Okamura

2016-02-01

In vivo tau imaging allows a deeper understanding of tau deposition in the brain, providing insights into the causes, diagnosis an..

Untangling tau imaging.

Victor L Villemagne, Nobuyuki Okamura, Christopher C Rowe

2016-01-01

In vivo imaging of tau deposits is providing a better understanding of the temporal and spatial tau deposition in the brain, allow..

Tau imaging: early progress and future directions

Victor L Villemagne, Michelle T Fodero-Tavoletti, Colin L Masters, Christopher C Rowe

2015-01-01

Use of selective in-vivo tau imaging will enable improved understanding of tau aggregation in the brain, facilitating research int..

In vivo tau imaging: Obstacles and progress

Victor L Villemagne, Nobuyuki Okamura

2014-06-01

The military conflicts of the last decade have highlighted the growing problem of traumatic brain injury in combatants returning f..

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using F-18-THK5105 PET

Nobuyuki Okamura, Shozo Furumoto, Michelle T Fodero-Tavoletti, Rachel S Mulligan, Ryuichi Harada, Paul Yates, Svetlana Pejoska, Yukitsuka Kudo, Colin L Masters, Kazuhiko Yanai, Christopher C Rowe, Victor L Villemagne

2014-06-01

Non-invasive imaging of tau pathology in the living brain would be useful for accurately diagnosing Alzheimer's disease, tracking ..

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease

Victor L Villemagne, Shozo Furumoto, Michelle T Fodero-Tavoletti, Rachel S Mulligan, John Hodges, Ryuichi Harada, Paul Yates, Olivier Piguet, Svetlana Pejoska, Vincent Dore, Kazuhiko Yanai, Colin L Masters, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura

2014-05-01

PURPOSE: Diagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A n..

Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies

Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura, Victor L Villemagne

2014-01-01

INTRODUCTION: The introduction of tau imaging agents such as (18)F-THK523 offers new hope for the in vivo assessment of tau deposi..